First use of 68Ga-NI-FAPI PET/CT for cancer diagnosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and diagnostic effectiveness of a new radiotracer, 68Ga-NI-FAPI, in patients with various types of cancer. The radiotracer targets carcinoma-associated fibroblasts, which are commonly overexpressed in malignant tumors. The study aims to assess how well this new agent can visualize tumors using PET/CT imaging, along with its biodistribution and radiation dosimetry. By focusing on a specific marker found in over 90% of epithelial malignant tumors, this approach could enhance cancer diagnosis and management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Various solid tumors with available histopathological findings
* Signed informed consent

Exclusion Criteria:

* pregnant or lactational women
* who suffered from severe hepatic and renal insufficiency

Where it's running

• Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
  Fuzhou, Fujian, China Recruiting

Study contacts

• Principal investigator: Weibing Miao, MD — First Affiliated Hospital of Fujian Medical University
• Study coordinator: Weibing Miao, MD
• Email: miaoweibing@126.com
• Phone: +86-0591-87981618

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MK-2010 with Sac-TMT in advanced solid tumors

  This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.

  Recruiting at 4 sites Phase 2 Merck Sharp & Dohme LLC · San Antonio, Texas and 3 other locations · NCT07785609

• Belzutifan in adolescents with solid tumors

  This study tests belzutifan in teenagers whose solid tumors can't be removed by surgery or have spread.

  Recruiting at 10 sites Phase 2 Merck Sharp & Dohme LLC · Iowa City, Iowa and 9 other locations · NCT07700758

• Ifinatamab Deruxtecan in kids with relapsed or refractory solid cancers

  This study tests whether I-DXd can help children whose solid tumors have come back or not responded to previous treatments.

  Recruiting at 35 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 34 other locations · NCT07630974

• MK-4884 safety in advanced solid tumors

  This early-phase study tests different doses of MK-4884 to see if it is safe and tolerable for adults with certain advanced solid cancers.

  Recruiting at 10 sites Phase 1 Merck Sharp & Dohme LLC · St Louis, Missouri and 9 other locations · NCT07600749

• PET scan targeting CDH3 for lung tumors

  This will test whether a new PET imaging agent called 68Ga-TOI-1 that targets CDH3 can better detect and stage lung tumors and help tell malignant from benign pulmonary nodules in adults with suspected or confirmed non-small cell lung cancer.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07487883

• Dabrafenib and trametinib for rare cancers with BRAF V600 mutations

  This arm tests whether dabrafenib and trametinib can help adults, children, and teens with cancers that have a BRAF V600 mutation.

  Recruiting at 15 sites Phase 2/3 Cancer Research UK · Belfast and 26 other locations · NCT07440290

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.